American Urological Association Annual Meeting | Conference

Panvac Plus BCG Does Not Significantly Delay Recurrence in Advanced NMIBC

September 13th 2021

The addition of a recombinant pox-viral vector vaccine Panvac™ to bacillus Calmette-Guérin did not significantly improve clinical outcomes for patients with BCG-unresponsive non–muscle invasive bladder cancer.

Masitinib Plus Docetaxel Produces PFS Benefit in mCRPC With Low Metastatic Involvement

September 13th 2021

The investigational small molecule masitinib plus docetaxel resulted in a statistically significant 21% reduction in the risk of progression or death compared with placebo plus docetaxel in men with metastatic castration-resistant prostate cancer and baseline alkaline phosphatase levels of 250 IU/mL or less.

Avelumab Plus BCG Induction Shows Favorable Tolerability in BCG-Unresponsive NMIBC

September 13th 2021

The addition of avelumab to Bacillus Calmette-Guerin induction therapy appeared to be safe and well tolerated in patients with BCG-unresponsive non–muscle invasive bladder cancer.

Systemic Review Underscores Need for Smoking Status Data on Genitourinary Cancer Trials

September 13th 2021

Smoking status is not often reported on genitourinary cancer clinical trials, which limits understanding of how smoking impacts the treatment, survival, and quality of life of this patient population.

Olaparib/Pembrolizumab Combo Continues to Show Promising Activity in mCRPC

September 12th 2021

The combination of olaparib and pembrolizumab continued to demonstrate antitumor activity in patients with metastatic castration-resistant prostate cancer who previously received docetaxel.

Dr. Kaplan on Real-World Surgical Retreatment Rates in LUTS/BPH

September 12th 2021

Steven Kaplan, MD, discusses real-world surgical retreatment rates in patients with lower urinary tract symptoms/benign prostatic hyperplasia.

Darolutamide Delays Time to Deterioration in HRQoL Related to Urinary and Bowel Symptoms in nmCRPC

September 12th 2021

Darolutamide was linked with a reduction in locally invasive procedures, delayed time to deterioration in health-related quality of life related to urinary and bowel symptoms in patients with nonmetastatic castration-resistant prostate cancer.

Enzalutamide/ADT Maintains Efficacy Regardless of Prior Antiandrogen Therapy in mHSPC

September 12th 2021

Enzalutamide plus androgen-deprivation therapy produced clinical benefit over ADT alone in patients with metastatic hormone-sensitive prostate cancer, regardless of prior antiandrogen therapy and its pretreatment duration.

Dr. Williams on the Rationale for the SunRISE-2 Trial in Muscle-Invasive Bladder Cancer

September 12th 2021

Stephen B. Williams, MD, discusses the rationale for the phase 3 SunRISE-2 trial in muscle-invasive bladder cancer.

MSI-H/dMMR Prostate Cancer Linked With Response to Checkpoint Blockade

September 11th 2021

Patients with microsatellite instability–high or mismatch repair–deficient prostate cancer may be more likely to respond to treatment with checkpoint inhibitors compared with those who have high tumor mutational burden.

Prognostic Risk Group, Receipt of Subsequent Therapies May Impact OS in mCRPC Receiving Lutetium 177

September 11th 2021

Cancer and Leukemia Group B prognostic risk group and the receipt of subsequent FDA-approved life-prolonging therapies may impact overall survival in patients with metastatic castration-resistant prostate cancer who are receiving lutetium 177.

Nadofaragene Firadenovec Sustains Efficacy in Advanced NMIBC in Longer-Term Follow-Up

September 11th 2021

Nadofaragene firadenovec, a novel intravesical gene therapy for patients with bacillus Calmette-Guérin unresponsive non–muscle invasive bladder cancer, demonstrated sustained durability according to findings from 2 cohorts of a phase 3 study.

Relugolix Induces Similar Rates of Castration Resistance–Free Survival Vs Leuprolide in Advanced Prostate Cancer

September 11th 2021

Relugolix failed to significantly delay onset of castration resistance compared with standard of care leuprolide in men with advanced prostate cancer.

Durvalumab/Vicineum Combo Shows Early Safety, Activity in High-Grade NMIBC

September 11th 2021

The combination of durvalumab and Vicineum was found to be well tolerated and to elicit complete responses in patients with Bacillus-Calmette Guérin–unresponsive non–muscle invasive bladder cancer.

Lutetium-PSMA Appears Safe in Locally Advanced High-Risk Prostate Cancer

September 11th 2021

Treatment with neoadjuvant lutetium prostate-specific membrane antigen followed by radical prostatectomy exhibited a favorable safety profile in patients with locally advanced high-risk prostate cancer.

TAR-200/Cetrelimab Under Investigation in Muscle-Invasive Bladder Cancer

September 11th 2021

TAR-200 plus cetrelimab may offer a superior treatment option for patients with muscle-invasive bladder cancer, and to answer this questions, investigators have initiated the randomized, phase 3 SunRISe-2 trial.

Nivolumab Plus Ipilimumab Response Signals Change for Cytoreductive Nephrectomy in Advanced RCC

September 11th 2021

Primary tumor response to nivolumab plus ipilimumab observed results of a Japanese study indicates a changing role for the timing of cytoreductive nephrectomy for patients with advanced renal cell carcinoma.fr

Dr. Tewari on the Benefits of Robotic Radical Prostatectom​y​ in Prostate Cancer

September 10th 2021

Ashutosh K. Tewari, MD, discusses the benefits of robotic radical prostatectom​y in prostate cancer.

Dr. Palese on Emerging Technologies in Benign Prostatic Hyperplasia

September 10th 2021

Michael A. Palese, MD, discusses emerging technologies in benign prostatic hyperplasia.

Dr. Badani on Utilizing Multiport Robotic Retroperitoneal Partial Nephrectomies in RCC

September 10th 2021

Ketan K. Badani, MD, discusses the utility of multiport robotic retroperitoneal partial nephrectomies in renal cell carcinoma (RCC).

NEXT PAGE
PREVIOUS PAGE
x